Patricia A. McNiff

TL;DR: Two novel pharmacological agents, CP-424,174 and CP-412,245, are identified as potent inhibitors of stimulus-coupled IL-1beta post-translational processing and act as selective cytokine release inhibitors and define a new therapeutic approach for controllingIL-1 production in inflammatory diseases.

TL;DR: In vitro studies of intracellular pH (pHi) indicate that tenidap is a potent anion-transport inhibitor and modulator of pHi, and within the appropriate cell or tissue microenvironment, these activities may contribute toTenidap's novel therapeutic profile.

TL;DR: With the guidance of a homology model of the GR ligand binding domain, structural modifications to 2 were successful in replacing the allyl and propynyl side chains with groups likely to be more chemically stable and less likely to produce toxic metabolites.

TL;DR: The ability of monocytes to produce radiolabeled pro‐IL‐1β in response to LPS and to posttranslationally process the procytokine after ATP stimulation was affected both by time in culture and by the presence of specific media components.

TL;DR: Synovial fluid recovered from an inflamed joint contains all the necessary cytokines in balance with inhibitors to promote SAA production by Hep3B cells, indicating that the relationship between the circulation and the liver that likely exists in rheumatoid arthritis patients is not mimicked.